Jcog 9511
Web24 ago 2010 · JCOG-9511 indicates Japan Clinical Oncology Group 9511 trial; SWOG-0124, Southwest Oncology Group 0124 trial. Treatment Delivery and Dose Intensity In … Web16 gen 2024 · Cisplatin combined with etoposide (EP) or irinotecan (IP) are two of the most commonly used chemotherapeutic regimens for first-line treatment of ES-SCLC. In particular, IP is widely used in Japan as first-line treatment based on the results of a Japanese phase III trial (JCOG 9511) and a meta-analysis including this clinical trial [3,4,5].
Jcog 9511
Did you know?
Web1 giu 2004 · However, SCLC israrely cured, although the responserate has been improved and the survivaltime extended through the useof chemotherapy. Based on the resultsof JCOG 9511 and JCOG 9902-DI, a randomized trial comparing IPwith IPE administered every 3 weeksin patients with previously untreatedED-SCLC is now being performed … Web2 mar 2024 · 9511 Phase III ... The JCOG Lung Cancer Study Group has been carrying out clinical studies, exploring new strategies of treatment, supportive therapies (antiemetics, etc.), etc., for a variety of cancers, including not only …
Web1 apr 2016 · JCOG 9511 might be the main resource of heter ogeneity in . OS meta‑analysis. The great treatment effect of IP r egimens . in the interim analyses led to the early stopping of JCOG . Web17 mar 2014 · The incidence of the greatest toxicity concern in JCOG 9511, grade 3 to 4 diarrhea, was 7.7% in this study (16.0% in JCOG 9511). The incidence of diarrhea was lower, which was most likely the.
http://www.jcog.jp/document/9511.htm
Web1 apr 2005 · Given the activity of and excellent tolerability of single-agent pemetrexed and pemetrexed/platinum combinations in NSCLC as well as the success of the substitution …
Web1 set 2010 · In contrast in the S0124 and JCOG-9511 trials, IP cycles were repeated every 4 weeks leading to lower dose intensities of irinotecan and cisplatin [9]. In addition, in studies of primarily Western patients with SCLC-ED, those with a WHO PS of two were ineligible whereas they represented 10% of patients in the JCOG-9511 study [7]. recherche chiots gratuitWebIrinotecan and cisplatin versus etoposide and cisplatin in small-cell lung cancer: JCOG 9511 Clin Lung Cancer. 2000 Aug;2(1):23-4. Authors M D Fisher, A D'Orazio. PMID: … unlink cod mobile from activisionWeb日本（jcog） あり 試験名 ：進展型小細胞肺癌におけるシスプラチン＋イリノテカンvs シスプラチン＋エトポシドの多施設ランダム化第3相比較試験（JCOG9511試験） unlink codes for firestickWeb17 mar 2014 · In 2002, a phase III trial conducted by the Japan Clinical Oncology Group (JCOG 9511) demonstrated the superiority of irinotecan plus cisplatin (IP) over EP for patients with ED-SCLC. 4 Median survival time (MST) and 1-year survival for the IP and EP arms were 12.8 versus 9.4 months and 58.4% versus 37.7%, respectively, but patients in … recherche christian munichWebJCOG trials (Noda et al, 2002). The data of JCOG 9511 are clearly interesting, however, only 154 patients have been randomised. It is essential to evaluate the reproducibility of … unlink commandWebcal Oncology Group (JCOG) 9511 trial demonstrated that cisplatin plus irinotecan (CPT-11) improved overall survival (OS) compared with a cisplatin plus etoposide regimen in … unlink computer from microsoft accountWeb6 apr 2009 · Over the past two decades, the cornerstone of therapy for extensive-stage SCLC has been a platinum compound (either carboplatin or cisplatin) in combination with the topoisomerase-II inhibitor etoposide. 7 In 2002, a Japanese phase III study (Japan Clinical Oncology Group [JCOG] 9511) comparing etoposide plus cisplatin (EP) with … unlink computer from onedrive windows 11